Teva Pharmaceutical Industries Limited
TEVA NYSEHealthcare ★★★★★Latest Earnings Below forecast↓
Date
Jul 29, 2026
ET
EPS Est.
0.08
EPS Actual
0.02
Revenue Est.
$4.02B
Revenue Actual
$4.14B
Next Earnings Report
Date
Nov 4, 2026 · Wed
Time
Pre-market
Fiscal Period
FY2026 Q3
EPS Est.
0.73
Revenue Est.
$4.23B
Company Overview
Teva Pharmaceutical Industries Limited (ticker TEVA) is listed on NYSE with a market cap of about $43.49B. Its next earnings report (FY2026 Q3) is expected on Nov 4, 2026 (ET), Pre-market, with consensus EPS of 0.73. In the last 15 reported quarters, EPS beat consensus estimates 11 times.
Actual EPS TrendRecently15Term · Feb 8, 2023 → Jul 29, 2026
Feb 8, 2023Range: 0.02 ~ 1.00Jul 29, 2026
Earnings History
| Date | Fiscal Period | EPS Est. | EPS Actual | Revenue Est. | Revenue Actual |
|---|---|---|---|---|---|
| Jul 29, 2026 | -- | 0.08 | Below forecast↓0.02 | $4.02B | $4.14B |
| Apr 29, 2026 | -- | 0.50 | 0.53 | $3.79B | $3.98B |
| Jan 28, 2026 | -- | 0.65 | Above forecast↑0.96 | $4.32B | $4.71B |
| Nov 5, 2025 | -- | 0.68 | 0.78 | $4.45B | $4.48B |
| Jul 30, 2025 | -- | 0.63 | 0.66 | $4.36B | $4.18B |
| May 7, 2025 | -- | 0.47 | 0.52 | $4.38B | $3.89B |
| Jan 29, 2025 | -- | 0.69 | 0.71 | $4.1B | $4.23B |
| Nov 6, 2024 | -- | 0.65 | 0.69 | $4.12B | $4.33B |
| Jul 31, 2024 | -- | 0.57 | 0.61 | $4.1B | $4.16B |
| May 8, 2024 | -- | 0.51 | 0.48 | $3.73B | $3.83B |
| Jan 31, 2024 | -- | 0.75 | Above forecast↑1.00 | $4.03B | $4.46B |
| Nov 8, 2023 | -- | 0.60 | 0.60 | $3.73B | $3.85B |
| Aug 2, 2023 | -- | 0.54 | 0.56 | $3.71B | $3.88B |
| May 10, 2023 | -- | 0.57 | Below forecast↓0.40 | $3.62B | $3.66B |
| Feb 8, 2023 | -- | 0.68 | 0.71 | $3.89B | $3.88B |
Original Filings (SEC)
10-Q2026-07-29 ↗
8-K2026-07-29 ↗
8-K2026-05-28 ↗
10-Q2026-04-29 ↗
8-K2026-04-29 ↗
10-K2026-02-03 ↗
8-K2026-01-28 ↗
8-K2026-01-12 ↗
Links point to the company's original filings on the U.S. Securities and Exchange Commission (SEC) website.
Report dates are US trading days (Eastern Time); EPS and revenue estimates are market consensus, in USD. This page is for reference only and does not constitute investment advice.
